12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eliquis apixaban regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Eliquis apixaban from Bristol-Myers and partner Pfizer to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF) with >=1 risk...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >